Lamassu BioTech

𝐓𝐡𝐞 𝐆𝐮𝐚𝐫𝐝𝐢𝐚𝐧

Often called the “Guardian of the Genome,” p53 is a crucial tumor suppressor gene that prevents tumor formation by inducing programmed cell death. When the DNA in a cell becomes damaged p53 plays a critical role in determining whether the cancerous cell survives. If the DNA can be repaired, p53 activates other genes to fix the damage. If the DNA cannot be repaired, The Guardian prevents the cell from dividing and signals it to undergo apoptosis. By stopping cells with mutated or damaged DNA from dividing, p53 helps prevent the development of tumors.

Visit www.lamassubiotech.com/sa53/ to learn more about how Lamassu Biotech’s novel genetically targeted SA53 therapy that works with p53 to fight up to 50 percent of all cancers.

Lamassu Biotech's team is on the road this week. Head of Business Development Olivier Jarry will be attending Sach Associates' first annual European Healthcare Impact Summit and the 26th annual Biotech in Europe Forum.

October is Breast Cancer Awareness Month, a time to raise awareness, show support, and take action in the fight against breast cancer. Whether you're a survivor or someone battling breast cancer diagnosis, our team at Lamassu Biotech honors and supports you.

Nearly 2 million Americans receive a cancer diagnosis each year. But government agencies and researchers have traditionally—and understandably—focused on more common cancers that affect the largest numbers of patients. This can leave people battling a rare cancer diagnoses with few treatment options. At Lamassu Biotech our novel genetically targeted therapy SA53, works by triggering the body’s natural defense mechanism, p53, which inhibits or blocks a protein called MDM2. The p53 pathway is one of the most important natural defense mechanisms your body has against cancer. Learn more at LamassuBiotech.com/sa53/.

September is Childhood Cancer Awareness Month. It shines a light on children with cancer and the challenges they face each and every day. While the overall outlook for children and adolescents with cancer has improved greatly over the last half-century, an estimated 1,600 kids in the U.S. lose their battle with cancer each year, making it the leading cause of death by disease among children. At Lamassu Biotech, we work every day to bring hope and healing to these young people.

During , hosted by the Liposarcoma Support Network, Lamassu Biotech CSO Dr. Greg Palmer will provide attendees with an update about ongoing Phase 1/2 trial of SA-53, a targeted therapy that activates p53, the "Guardian of Genome" to kill cancer tumors. The treatment is currently being investigated in adult patients with sarcoma, who currently have limited therapeutic options, and is already showing favorable phase 1 safety data.

July is Sarcoma Awareness Month. Lamassu Biotech's pioneering therapy, SA-53, has the potential to transform the way we treat cancer. This groundbreaking treatment is being investigated in adult patients with sarcoma and other solid tumors who possess the p53 wild-type gene and who currently have limited therapeutic options. It’s just one of the ways we’re bringing hope and healing to those who need it most. Learn more at www.LamassuBiotech.com.